Status:
RECRUITING
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18+ years
Brief Summary
In 2024, the prevalence of TTR cardiac amyloidosis is difficult to determine precisely. Indeed, the disease has long been underdiagnosed due to a lack of effective treatment and non-invasive diagnosti...
Eligibility Criteria
Inclusion
- Sujet majeur (≥18 ans)
- Diagnostic d'amylose à TTR suite à une hospitalisation en médecine interne aux HUS entre 01/01/2013 au 31/12/2023.
Exclusion
- Subject (and/or their legal representative, if applicable) who has expressed their opposition to the reuse of their data for scientific research purposes.
- Type of amyloidosis other than ATTR after review of the medical record (immunological assessment, imaging assessment, expert report).
Key Trial Info
Start Date :
April 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 22 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06907836
Start Date
April 22 2024
End Date
December 22 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Médecine Interne - CHU de Strasbourg - France
Strasbourg, France, 67091